UBS Knock-Out ABT/ DE000UL2Q3Y3 /
08/11/2024 21:55:15 | Diferencia+0.180 | Bid- | Ask- | Subyacente | Precio de ejercicio | Fecha de expiración | Tipo de opción |
---|---|---|---|---|---|---|---|
4.800EUR | +3.90% | - Volumen de oferta: - |
- Tamaño/ Volumen/ Formato de Ask: - |
Abbott Laboratories | 65.9748 USD | 31/12/2078 | Call |
GlobeNewswire
06/08
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results
GlobeNewswire
06/06
Circana’s 2023 New Product Pacesetters Report Reveals Innovation Is Meeting Consumers in New Moments
GlobeNewswire
09/05
R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new Pre...
GlobeNewswire
25/03
Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer
GlobeNewswire
15/03
Attention Reckitt Benckiser Group investors: Portnoy Law Firm Announces Investigation into Reckitt B...
GlobeNewswire
14/11/2023
NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports In...
GlobeNewswire
19/10/2023
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
- Primera página
- Atrás
- 1
- 2
- 3
- 4
- Siguiente
- Última página